Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun

This article was originally published in PharmAsia News

Executive Summary

Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets

You may also be interested in...



Hisun-Pfizer Split: What Went Wrong And What Next?

The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.

New Growth Models In China: McKinsey-PharmAsia Summit Report Preview

With increased pricing pressure on branded generics, MNCs in China need to fundamentally redesign their business models with stronger market-access capabilities and to shift resources away from brands under acute pressure to support those with bigger future potential, according to a survey conducted by McKinsey & Company.

New Growth Models In China: McKinsey-PharmAsia Summit Report Preview

With increased pricing pressure on branded generics, MNCs in China need to fundamentally redesign their business models with stronger market-access capabilities and to shift resources away from brands under acute pressure to support those with bigger future potential, according to a survey conducted by McKinsey & Company.

Related Content

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel